Chemomab Therapeutics (CMMB) Earnings Date, Estimates & Call Transcripts $1.16 -0.04 (-3.33%) (As of 11:50 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 14EstimatedActual EPS (Aug. 21) -$0.26 Missed By -$0.06 Consensus EPS (Aug. 21) -$0.20 Conference Call Transcript Get Chemomab Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CMMB and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCMMB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CMMB Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. Chemomab Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.02)($0.02)($0.02)Q2 20241($0.02)($0.02)($0.02)Q3 20241($0.02)($0.02)($0.02)Q4 20241($0.02)($0.02)($0.02)FY 20244($0.08)($0.08)($0.08)Q1 20251($0.20)($0.20)($0.20)Q2 20251($0.20)($0.20)($0.20)Q3 20251($0.20)($0.20)($0.20)Q4 20251($0.20)($0.20)($0.20)FY 20254($0.80)($0.80)($0.80)CMMB Earnings Date and InformationChemomab Therapeutics last posted its quarterly earnings data on August 21st, 2024. The reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.06. Chemomab Therapeutics has generated ($1.60) earnings per share over the last year (($1.60) diluted earnings per share). Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.80) per share. Chemomab Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off prior year's report dates.Read More Chemomab Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/21/2024Q2 2024($0.20)($0.26)($0.06)($0.26)-- 5/9/2024Q1 2024($0.20)($0.28)($0.08)($0.28)--3/7/2024Q4 2023($0.40)($0.26)+$0.14($0.26)-- 11/9/2023Q3 2023($0.60)($0.34)+$0.26($0.34)--8/14/2023Q2 2023($0.80)($0.72)+$0.08($0.72)--5/11/2023Q1 2023($0.80)($0.80)-($0.80)-- Get the Latest News and Ratings for CMMB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/20/2023Q4 2022($0.80)($0.72)+$0.08($0.72)--11/11/2022Q3 2022($0.60)($0.70)($0.10)($0.70)--8/12/2022Q2 2022($0.60)($0.54)+$0.06($0.54)--5/12/2022Q1 2022($0.40)($0.44)($0.04)($0.44)--3/9/2022Q4 2021($0.40)($0.44)($0.04)($0.44)--11/11/2021Q3 2021($0.02)($0.26)($0.24)($0.26)--8/12/2021Q2 2021($0.27)($0.26)+$0.01($0.26)--5/12/2021Q1 2021($0.43)($0.22)+$0.21($0.22)--3/9/2021Q4 2020($8.00)($4.00)+$4.00($4.00)--11/16/2020Q3 2020($7.20)($5.60)+$1.60($5.60)--8/14/2020Q2 2020($8.80)($7.20)+$1.60($7.20)--5/7/2020Q1 2020($8.80)($6.56)+$2.24($5.12)--3/17/2020Q4 2019($2.08)$31.84+$33.92$40.48--11/15/2019Q3 2019($2.40)($36.16)($33.76)($36.16)-- Chemomab Therapeutics Earnings - Frequently Asked Questions When is Chemomab Therapeutics's earnings date? Chemomab Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on CMMB's earnings history. Did Chemomab Therapeutics beat their earnings estimates last quarter? In the previous quarter, Chemomab Therapeutics (NASDAQ:CMMB) missed the analysts' consensus estimate of ($0.20) by $0.06 with a reported earnings per share (EPS) of ($0.26). Learn more on analysts' earnings estimate vs. CMMB's actual earnings. How can I read Chemomab Therapeutics's conference call transcript? The conference call transcript for Chemomab Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Chemomab Therapeutics generate each year? Chemomab Therapeutics (NASDAQ:CMMB) has a recorded net income of -$24.22 million. CMMB has generated -$1.60 earnings per share over the last four quarters. What is Chemomab Therapeutics's EPS forecast for next year? Chemomab Therapeutics's earnings are expected to grow from ($1.00) per share to ($0.80) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Cue Biopharma Earnings Aerovate Therapeutics Earnings Omega Therapeutics Earnings Mural Oncology Earnings CEL-SCI Earnings Kronos Bio Earnings SCYNEXIS Earnings Theratechnologies Earnings Calidi Biotherapeutics Earnings Upexi Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles: Nike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season? This page (NASDAQ:CMMB) was last updated on 10/15/2024 by MarketBeat.com Staff From Our PartnersHave you heard of Donald Trump’s Project Crypto?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
